what is the first cryptocurrency, People searches

Mengke Pharmaceutical Co., Ltd.: The new packaging of Contizontamide tablets will be on the market soon. Mengke Pharmaceutical Co., Ltd. announced that the company has launched Contizontamide tablets with new packaging specifications, and a box of 12 tablets will be on the market soon. Contizontamide tablet is a new class 1 oxazolidinone antibacterial drug with global intellectual property rights. It was approved by National Medical Products Administration, China on June 1st, 2021 for the treatment of complex skin and soft tissue infections.Jinmo Technology: The reserve price for the transfer of 40% equity of Mo Tian Jun Fu is 9,980,600 yuan. Jinmo Technology announced that the company held the 28th meeting of the 4th Board of Directors on November 29th, 2024, and reviewed and approved the Proposal on Authorizing the General Manager's Office to Transfer the Equity of Joint Venture. Authorized by the resolution of the board of directors, the company entrusted Southwest United Assets and Equity Exchange to publicly list and transfer 40% equity of Beijing Mo Tian Jun Fu Private Equity Fund Management Co., Ltd., with a reserve price of 9,980,600 yuan. Aerofilm Technology Development Group Co., Ltd. became the final transferee, with a transaction price of 9,980,600 yuan. Aerofilm Technology holds 23.63% shares of Jinmo Technology, which is the controlling shareholder of the company and also the shareholder holding more than 5% shares. This transaction constitutes a connected transaction.Jinmo Technology: The reserve price for the transfer of 40% equity of Mo Tian Jun Fu is 9,980,600 yuan. Jinmo Technology announced that the company held the 28th meeting of the 4th Board of Directors on November 29th, 2024, and reviewed and approved the Proposal on Authorizing the General Manager's Office to Transfer the Equity of Joint Venture. Authorized by the resolution of the board of directors, the company entrusted Southwest United Assets and Equity Exchange to publicly list and transfer 40% equity of Beijing Mo Tian Jun Fu Private Equity Fund Management Co., Ltd., with a reserve price of 9,980,600 yuan. Aerofilm Technology Development Group Co., Ltd. became the final transferee, with a transaction price of 9,980,600 yuan. Aerofilm Technology holds 23.63% shares of Jinmo Technology, which is the controlling shareholder of the company and also the shareholder holding more than 5% shares. This transaction constitutes a connected transaction.

Botuo Bio: Adjust the profit distribution plan for the first three quarters of 2024. Botuo Bio announced that the total amount of cash dividends to be distributed in the company's profit distribution for the first three quarters of 2024 was adjusted from RMB 52.2583 million to RMB 53.2083 million. Before the adjustment, the company's total share capital was 105 million shares after deducting the shares in the company's repurchase special securities account, and a total cash dividend of 52.2583 million yuan was planned to be distributed. After adjustment, the company's total share capital is 107 million shares, of which 250,000 shares are repurchased in the special securities account, and the total number of shares actually participating in the profit distribution of the company is 106 million shares, with a total cash dividend of 53,208,300 yuan.Nordic United Bank: The risk of the European Central Bank cutting interest rates by 50 basis points cannot be ignored. Nordic United Bank said that the European Central Bank may cut interest rates by 25 basis points again, but there is also a significant risk of cutting interest rates by 50 basis points. The differences within the Committee have intensified again, and it is not easy for Lagarde to get another consistent compromise. A possible compromise is to cut interest rates by 25 basis points, and at the same time, some guidelines are given, indicating that as long as the ECB's benchmark view remains unchanged, it may cut interest rates again in January. Our benchmark expectation is still to cut interest rates by 25 basis points before the meeting in April next year, when the deposit interest rate is expected to reach 2.25%.Kremlin spokesman: (Asked if Putin has been invited to attend Trump's inauguration ceremony) No invitation has been received.

By 2029, China will build about 10,000 superior specialties of traditional Chinese medicine. According to state administration of traditional chinese medicine, China will promote the construction of superior specialties of traditional Chinese medicine at different levels to further improve the clinical efficacy of traditional Chinese medicine. By 2029, the overall scale of superior specialties of traditional Chinese medicine will reach about 10,000. Recently, state administration of traditional chinese medicine issued opinions on accelerating the construction of superior specialties of traditional Chinese medicine, and put forward the requirements of strengthening the planning and layout of superior specialties of traditional Chinese medicine and promoting the construction of superior clusters of traditional Chinese medicine. (CCTV News)IEA Monthly Report: The decision of OPEC+has reduced the potential oversupply. The International Energy Agency (IEA) said today that the recent decision of OPEC+member countries to postpone the planned production increase has "greatly reduced" the potential oversupply next year. Nevertheless, IEA said that in view of the persistent overproduction in some OPEC+member countries, strong supply growth outside the alliance and moderate global oil demand growth, there may still be a serious oversupply in the oil market in 2025. IEA predicts that even if all OPEC+production reduction plans remain unchanged, supply will exceed demand by about 950,000 barrels per day next year. IEA said that if OPEC members start increasing production in April as planned, the oversupply will increase to 1.4 million barrels per day.Mengke Pharmaceutical Co., Ltd.: The new packaging of Contizontamide tablets will be on the market soon. Mengke Pharmaceutical Co., Ltd. announced that the company has launched Contizontamide tablets with new packaging specifications, and a box of 12 tablets will be on the market soon. Contizontamide tablet is a new class 1 oxazolidinone antibacterial drug with global intellectual property rights. It was approved by National Medical Products Administration, China on June 1st, 2021 for the treatment of complex skin and soft tissue infections.